Abstract: A butterfly door hinge and a vehicle having the same are provided, which includes a mounting base, a door connecting arm, a hinge connecting arm, and a limiting assembly, wherein the hinge connecting arm has one end hinged with the mounting base, and the other end hinged with the door connecting arm; the limiting assembly includes a planar limiting portion arranged on the mounting base, and a limiting body arranged on the door connecting arm, the limiting body having a spiral-type outer contour. In the disclosure, first the hinge connecting arm is used to constrain the door to swing along a fixed point, and then a posture of the door is constrained through a frictional fit between the limiting body and the planar limiting portion.

Abstract: The present disclosure describes techniques for voice-controlled content creation. The techniques comprise monitoring voice commands spoken by a creator. Recording of a content may be initiated in response to recognizing a first voice command spoken by the creator. Recording of the content may be stopped in response to recognizing a second voice command spoken by the creator. A timestamp associated with the second voice command may be created. A segment may be automatically deleted from the content based on the timestamp. The segment may comprise a recording of the second voice command.

Abstract: An autonomous mobile device (AMD) interacts with a user to provide tasks such as conveniently displaying information on a screen and moving with the user as they move. The AMD determines an area, or bounding box, of a user appearing within images obtained by a camera that is mounted on the AMD. A preferred area, with respect to the images, such as a center of the image, is specified to provide desired framing of images. As images are acquired by the camera, a difference between the bounding box and the preferred area is determined. Based at least in part on this difference, instructions are determined to move one or more of the cameras or the entire AMD to try and reframe the bounding box in subsequent images closer to the preferred area. Other factors, such as the user being backlit, may also be considered in determining the instructions.

Abstract: The present disclosure provides an anti-PD-L1/anti-B7-H3 multispecific antibody capable to effectively block the interaction between PD-L1 and its receptor PD-1, and suppress the T-cell inhibitory effect of B7-H3 protein. The multispecific antibody may have high binding affinity to both of a PD-L1 protein and a B7-H3 protein.

Abstract: The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.

Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.

Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.

Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.

Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.

Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.

Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.

Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.

Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.

Abstract: Techniques for performing rate control for encoding of video frames are provided. A first timestamp that indicates a prior video frame capture time and a second timestamp that indicates a current video frame capture time are received. A time difference between these timestamps is determined. An average video data bit encoding rate is multiplied by the determined time difference to calculate a bit budget. An indication of a number of encoded video data bits of the prior video frame and of any further video frames encoded subsequent to the prior video frame and prior to the current video frame is received. A virtual buffer fill level is adjusted based on a difference between the indicated number of encoded video bits and the calculated bit budget. A quantizer parameter is adjusted based on the adjusted virtual buffer fill level. The current video frame is encoded according to the adjusted quantizer parameter.

Abstract: Techniques for performing rate control for encoding of video frames are provided. A first timestamp that indicates a prior video frame capture time and a second timestamp that indicates a current video frame capture time are received. A time difference between these timestamps is determined. An average video data bit encoding rate is multiplied by the determined time difference to calculate a bit budget. An indication of a number of encoded video data bits of the prior video frame and of any further video frames encoded subsequent to the prior video frame and prior to the current video frame is received. A virtual buffer fill level is adjusted based on a difference between the indicated number of encoded video bits and the calculated bit budget. A quantizer parameter is adjusted based on the adjusted virtual buffer fill level. The current video frame is encoded according to the adjusted quantizer parameter.

Abstract: Methods, systems, and apparatuses for performing rate control for encoding of video frames are provided. A first timestamp is received that indicates a capture time for a prior video frame. A second timestamp is received that indicates a capture time for a current video frame. A time difference between the second timestamp and the first timestamp is determined. An average video data bit encoding rate is multiplied by the determined time difference to calculate a bit budget. An indication of a number of video data bits that have been encoded is received. The number includes a number of encoded video data bits of the prior video frame and of any further video frames encoded subsequent to the prior video frame and prior to the current video frame. A virtual buffer fill level is adjusted based on a difference between the indicated number of video bits that have been encoded and the calculated bit budget. A quantizer parameter is adjusted based on the adjusted virtual buffer fill level.